Molecular Pathology & Variant Genetics | SGCB Research Platform (LGMD R4 / 2E)

Structural Biochemistry

The "House of Cards" Assembly Cascade

The SGCB gene (chromosome 4q12, RefSeq NM_000232.5) encodes β-sarcoglycan (NP_000223.1; 318 amino acids, ~34.8 kDa core polypeptide / 43 kDa glycosylated glycoprotein, historically termed 43DAG). It is a Type II single-pass transmembrane protein with an intracellular N-terminus (aa 1–65), a single transmembrane helix (aa 66–86), and a large extracellular C-terminal domain (aa 87–318) containing three N-linked glycosylation sites (Asn158, Asn211, Asn258). In healthy skeletal and cardiac myocytes, β-sarcoglycan forms a stoichiometric 1:1:1:1 tetramer with α-, γ-, and δ-sarcoglycan within the dystrophin-glycoprotein complex (DGC) to dissipate mechanical shear stress during contraction.

β-Sarcoglycan Nucleation

Assembly within the endoplasmic reticulum is strictly ordered. Biochemical studies (Chan et al. J Cell Biol 1998, PMID: 9864373) demonstrate that β-sarcoglycan and δ-sarcoglycan form the mandatory core heterodimer scaffold. Without functional β-sarcoglycan, α and γ subunits cannot assemble into a stable complex.

Consequence: Secondary loss of the entire tetrameric complex at the sarcolemma.

ERAD Degradation

Misfolded β-sarcoglycan variants and uncomplexed sarcoglycan subunits (α, γ, δ) are recognized by endoplasmic reticulum quality control (ERQC) chaperones and mannosidases (Soheili et al. Hum Mutat 2012, PMID: 22095924). They undergo polyubiquitination and retrotranslocation to the 26S proteasome via ER-associated degradation (ERAD).

Phenotype: Severe or complete sarcoglycan deficiency despite normal SGCA, SGCG, SGCD genes.

Mechanical Rupture & Calpain

Deprived of the sarcoglycan complex, the sarcolemma becomes mechanically fragile under contractile shear strain. Extracellular calcium ([Ca²⁺] ~1–2 mM) enters the myoplasm ([Ca²⁺] ~100 nM), activating cytosolic μ-calpain (CAPN1) and m-calpain (CAPN2) proteases, mitochondrial Ca²⁺ overload, and progressive fibro-fatty muscle replacement.

Outcome: Progressive limb-girdle weakness and high risk of dilated cardiomyopathy.

Sequencing & Variant Annotation

Compound Heterozygous Class 5 Pathogenic Profile

Peer-reviewed molecular analysis of two well-characterized ACMG Class 5 pathogenic SGCB variants (NM_000232.5:c.[341C>T];[552T>G]) documented in international clinical genetics registries (ClinVar & LOVD).

Allele 1 • Exon 3 • Proximal Ectodomain Missense • Class 5

c.341C>T | p.(Ser114Phe)

ClinVar: VCV000042035 • Codon 114: TCT (Ser) → TTT (Phe)

Structural Consequence: A cytosine-to-thymine transition at nucleotide 341 in Exon 3 substitutes a polar serine at residue 114 with a bulky, hydrophobic phenylalanine within the proximal extracellular domain of β-sarcoglycan. It is one of the most recurrent pathogenic missense alleles in European LGMD R4 cohorts (Semplicini et al. Neurology 2015, PMID: 25862795).

Cellular Fate: Deep mutational scanning of all 6,340 possible SGCB amino acid substitutions (Li, Weihl, Haller et al. J Clin Invest 2023, PMID: 37317968) and functional expression studies confirm that p.Ser114Phe causes severe protein mislocalization: the full-length polypeptide is synthesized in the ER but intercepted by ER quality control and degraded via the ubiquitin-proteasome system (ERAD) before reaching the sarcolemma.

Peer-Reviewed Rescue Evidence (Preclinical): Experimental studies demonstrate that ER-retained missense sarcoglycan mutants often preserve residual complex-forming ability if rescued from premature ERAD degradation using ER α-mannosidase I inhibition (kifunensine; Soheili et al. Hum Mutat 2012, PMID: 22095924) or small-molecule protein folding correctors such as CFTR corrector C17 (Scano et al. Int J Mol Sci 2024, PMID: 39769077). Note: These small-molecule correctors remain in preclinical cell/animal research and are not yet clinically approved for LGMD R4.

Research Horizons: AAV gene replacement • Preclinical CFTR/ERAD correctors • Theoretical Adenine Base Editing (ABE).

Allele 2 • Exon 4 • Premature Stop Nonsense (PTC) • Class 5

c.552T>G | p.(Tyr184*)

ClinVar: VCV000008713 • Codon 184: TAT (Tyr) → TAG (Amber Stop / Ter)

Structural Consequence: A thymine-to-guanine transversion at nucleotide 552 in Exon 4 converts the wild-type tyrosine codon (TAT / UAU) into an amber premature termination codon (TAG / UAG) at amino acid position 184. This truncates the final 135 amino acids (residues 184–318) of the extracellular C-terminal domain, eliminating two N-linked glycosylation sites (Asn211, Asn258) and the conserved C-terminal cysteine-rich cluster essential for sarcoglycan complex stability.

Cellular Fate: Because Exon 4 (mRNA bases 470–661) lies well upstream of the final Exon 5/Exon 6 junction (mRNA base 793), this premature stop codon triggers canonical nonsense-mediated mRNA decay (NMD) or produces a severely truncated, non-functional polypeptide that is rapidly cleared, resulting in a loss-of-function null allele.

Clinical Literature Documentation: Documented as a pathogenic loss-of-function allele across multiple unrelated LGMD R4 families in international mutation spectrum studies (Trabelsi et al. Eur J Hum Genet 2008, PMID: 18285821; Semplicini et al. Neurology 2015, PMID: 25862795; foundational disease mechanism established by Bönnemann et al. Nat Genet 1995, PMID: 7581449).

Research Horizons: AAV full-length cDNA replacement • Theoretical Prime Editing / Read-Through.

Next: Gene Therapy & CRISPR Horizons

Explore the SRP-9003 Phase 3 EMERGENE trial data and in vivo base editing feasibility.

View Gene Therapy & CRISPR arrow_forward